Reviva Pharmaceuticals(RVPH) Stock Price Today

0.8750
-0.0020-0.23%

Trading Apr 30 09:34 ET

40.90MMarket Cap-0.97P/E (TTM)

SymbolStock Name

PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

This_Guy

Mar 31 00:19

$Reviva Pharmaceuticals (RVPH.US)$
Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress
Reviva Pharmaceuticals (NASDAQ: RVPH) has announced it will present topline data from the long-term open label extension portion of its Phase 3 RECOVER study for brilaroxazine in schizophrenia treatment at the 2025 SIRS Congress in Chicago.
The presentation, titled 'Brilaroxazine Phase 3 Recover 52-Week Open-Label Evaluation of Efficac...

Clintzilla

Jan 16 23:05

$Reviva Pharmaceuticals (RVPH.US)$ Institutions steal the whole float yet?

iDontKnowHowToTrade

Jan 2 23:23

$Reviva Pharmaceuticals (RVPH.US)$ LET IT FLYYY

Trytosaveabit

Dec 17, 2024 06:25

Of course! Hehehe

$Reviva Pharmaceuticals (RVPH.US)$ Reviva Announces Proposed Public Offering
GlobeNewswire· 6 mins ago

Jaguar8

Dec 16, 2024 21:00

NEWS

$Reviva Pharmaceuticals (RVPH.US)$
Reviva Announces Positive Preliminary Topline Data for the Long-Term Open Label Extension Portion of the Phase 3 RECOVER Study Evaluating Brilaroxazine in Schizophrenia
Monday, 16th December at 8:00 am
– Once daily brilaroxazine demonstrated favorable long-term safety and robust broad-spectrum efficacy sustained over 1-year –
– Generally well-tolerated with low rates of adverse events and discontinuation –
– Full data set from open-label extension (OLE) of R...

Market Insights

🎙️Discussion 1. China-EU EV negotiations kick off recently. How do you think the negotiations will impact the performance of related stocks Show More